Side-by-Side Comparison
BPC-157 vs TB-500: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how BPC-157 and TB-500 differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
BPC-157
L2Also: Body Protection Compound-157, Bepecin, PL 14736
A gastric pentadecapeptide studied extensively in animal models for tissue healing, gut protection, and cytoprotective properties. Despite over 100 preclinical studies, human clinical data remains extremely limited.
TB-500
L3Also: Thymosin Beta-4, TB4, Tβ4
A naturally occurring peptide central to cell migration and tissue repair. Phase 2 human wound healing trials showed accelerated healing; also studied for cardiac and corneal repair.
Side-by-side comparison
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Primary mechanism | Angiogenesis & VEGF Modulation | Actin Sequestration & Cell Migration |
| FDA status | Banned from Compounding (Category 2) | Banned from Compounding (Category 2) |
| Evidence level | Preclinical Evidence | Emerging Clinical Evidence |
| Human trials | Yes (3+ indexed) | Yes (3+ indexed) |
| Studies indexed | 128 total (3 human, 95 animal) | 119 total (4 human, 85 animal) |
| Primary uses researched | Tissue repair, Gut healing, Tendon recovery, Anti-inflammatory, Wound healing, Neuroprotection | Wound healing, Tissue repair, Anti-inflammatory, Hair growth |
| Administration routes | intramuscular, intraperitoneal (research), oral, subcutaneous, topical | subcutaneous |
| Molecular weight | 1419.53 Da | 4963.50 Da |
| Amino acids | 15 | 43 |
| Category | healing recovery | healing recovery |
| WADA status | Prohibited | Prohibited |
Key differences
Mechanism. BPC-157 acts primarily through angiogenesis & vegf modulation, while TB-500 acts primarily through actin sequestration & cell migration. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Both compounds share the same FDA status (Banned from Compounding (Category 2)), which means the practical pathway to access is similar for each.
Evidence base. TB-500 sits at a higher evidence level (L3) than BPC-157 (L2) under PeptideMark's L1–L5 methodology.
Research focus. Published research on BPC-157 has concentrated on tissue repair, gut healing, tendon recovery. Research on TB-500 has concentrated on wound healing, tissue repair, anti-inflammatory. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Documented effects | 7 total | 6 total |
| Serious events | 0 | 0 |
| Common events | 1 | 1 |
| Black box warning | No | No |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 3 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions |
Strengths & limitations
BPC-157
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Limited evidence base (L2)
- Prohibited in competitive sport under WADA
TB-500
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Prohibited in competitive sport under WADA
Representative studies
BPC-157
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Vasireddi N, Hahamyan H, Salata MJ, et al. · Sports Health (2025)
Despite broad preclinical support across muscle, tendon, ligament, and bone models, only one clinical study exists for musculoskeletal applications, leaving a significant gap between animal and human evidence.
PubMed 40756949Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Lee KY, Burgess MM. · Alternative Therapies in Health and Medicine (2025)
Intravenous BPC-157 up to 20mg was well-tolerated in 2 healthy adults with no measurable effects on heart, liver, kidney, thyroid, or glucose biomarkers. Plasma levels returned to baseline within 24 hours.
PubMed 40131143TB-500
Thymosin beta4 accelerates wound healing
Malinda KM, Sidhu GS, Mani H, et al. · Journal of Investigative Dermatology (1999)
Thymosin beta-4 accelerated wound healing by 42-61% and increased wound contraction by 11% through enhanced keratinocyte migration and angiogenesis.
PubMed 10469335Thymosin beta 4 promotes dermal wound healing and angiogenesis in vivo
Philp D, Goldstein AL, Kleinman HK. · Annals of the New York Academy of Sciences (2004)
Tβ4 accelerated wound closure across all animal models tested, with enhanced angiogenesis and hair follicle stem cell activation.
PubMed 15539408Frequently asked
What is the main difference between BPC-157 and TB-500?
BPC-157 is a gastric pentadecapeptide studied extensively in animal models for tissue healing, gut protection, and cytoprotective properties. despite over 100 preclinical studies, human clinical data remains extremely limited. Its primary mechanism is angiogenesis & vegf modulation. TB-500 is a naturally occurring peptide central to cell migration and tissue repair. phase 2 human wound healing trials showed accelerated healing; also studied for cardiac and corneal repair. Its primary mechanism is actin sequestration & cell migration. The two differ in regulatory status (Banned from Compounding (Category 2) vs Banned from Compounding (Category 2)), strength of evidence (L2 vs L3), and the primary conditions for which each is researched.
Is BPC-157 or TB-500 FDA approved?
BPC-157: BPC-157 was placed on the FDA Category 2 list (substances with safety concerns) in late 2023, prohibiting compounding pharmacies from producing it for human use under Section 503A. The FDA cited potential immune reactions, manufacturing impurities, and a lack of human safety data. BPC-157 is not FDA-approved for any human indication. There is no legal basis for selling it as a drug, food, or dietary supplement. The FDA has stated it may take enforcement action against compounding pharmacies that produce it. Several legal challenges to the Category 2 classification are ongoing. TB-500: Thymosin beta-4 placed on FDA Category 2 list in late 2023. Not approved for human use. Was previously available through compounding pharmacies.
How does the evidence base compare?
BPC-157 has 128 indexed studies (3 human, 95 animal) and is rated Preclinical Evidence. TB-500 has 119 indexed studies (4 human, 85 animal) and is rated Emerging Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can BPC-157 and TB-500 be compared directly?
Yes — both compounds share the healing recovery category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are BPC-157 and TB-500 commonly stacked together?
Yes — published literature and clinical practice sometimes combine BPC-157 and TB-500, typically for complementary mechanisms. Stacking should only be undertaken under qualified medical supervision, and evidence for combined safety is usually weaker than evidence for either compound alone.
Which has a better-documented safety profile, BPC-157 or TB-500?
BPC-157 has 7 documented side effects (0 serious). TB-500 has 6 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are BPC-157 and TB-500 administered?
BPC-157 is typically administered via intramuscular or intraperitoneal (research) or oral or subcutaneous or topical. TB-500 is typically administered via subcutaneous. Route differences affect onset, peak levels, and patient convenience.
Which is better, BPC-157 or TB-500?
"Better" depends on the therapeutic goal, regulatory context, and individual response. BPC-157 is most researched for tissue repair and gut healing; TB-500 is most researched for wound healing and tissue repair. FDA status also matters: Banned from Compounding (Category 2) for BPC-157 vs Banned from Compounding (Category 2) for TB-500. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
BPC-157 →
Full profile
TB-500 →